home / stock / ions / ions articles

IONS Articles, Ionis Pharmaceuticals Inc. - From 12/22/23

Stock Information
Company Name: Ionis Pharmaceuticals Inc.
Stock Symbol: IONS
Market: NASDAQ
Website: ionispharma.com
Menu
IONS IONS Quote IONS Short IONS News IONS Articles IONS Message Board
Get IONS Alerts

News, Short Squeeze, Breakout and More Instantly...
New Hope for Nerve Damage Patients as AstraZeneca/Ionis' Eplontersen Receives FDA Nod for Hereditary Amyloidosis Treatment | Benzinga

Friday, FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplonte...
Ionis' Strategic Shift Praised by Analysts For Donidalorsen's Global Reach | Benzinga

Monday, Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered into a license agreement with Otsuka Pharmaceutical Co Ltd under which...

Cathie Wood's Ark Invest Goes Shopping For Moderna Stock — Sells DraftKings Shares Amid Quarterly Rise In Revenue, EPS Beat | Benzinga

On Thursday, Cathie Wood-led Ark Invest made notable adjustments to its holdings, with a significant sale of DraftKings Inc (NASDAQ:DKNG) shares an...

Cathie Wood-Led Ark Invest Sells Over $6.5M Worth Of Tesla Stock, What's Going On? | Benzinga

On Tuesday, Cathie Wood-led Ark Invest made a significant move by selling over $6.5 million worth of Tesla Inc (NASDAQ:TSLA) shares. This sale come...
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges | Benzinga

Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY) for two undisclosed early-sta...

Why Ionis Pharmaceuticals Stock Popped Today | Benzinga

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) shares are trading higher Tuesday after the company announced the Phase 3 Balance study of olezarsen met...

Ionis Pharmaceuticals' Rare Metabolic Disorder Candidate Poised To Become New Standard Treatment, Study Shows Encouraging Action | Benzinga

Ionis Pharmaceuticals Inc (NASDAQ: IONS) released topline results for the Phase 3 Balance study of olezarsen in people with familial chylomicr...
Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope | Benzinga

Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-ex...

Previous 10 Next 10